What is CD30 expression?
CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others.
What is CD30 positive?
CD30-positive cells characterize lymphomatoid papulosis and anaplastic large cell lymphoma but can also be found in nonneoplastic skin disorders. Purportedly, CD30 is useful in the differential diagnosis between insect bites and lymphomatoid papulosis.
Is AITL CD30 positive?
Using a CD30 cutoff of 5%, prior studies have demonstrated that 63% of patients with AITL were CD30 positive, but only 5% were strongly positive (defined as greater than 50% of cells), thus potentially contributing to some of this discrepancy.
What is the CD30 cell?
PROH-teen) A protein found on some T cells and B cells (two types of white blood cells). It is a receptor for a protein called tumor necrosis factor, which is involved in cell growth and cell survival. The CD30 protein may be found in higher than normal amounts on some types of cancer cells, including lymphoma cells.
What is CD30 antibody?
CD30 has been identified as a marker on Reed–Sternberg cells in Hodgkin lymphoma and cells in other specific types of lymphoma. CD30 monoclonal antibodies may be used to treat Hodgkin’s lymphoma or anaplastic large cell lymphoma.
What is CD15 a marker for?
The glycan determinant CD15 (also known as Lewis x, or Le(x)) is a distinguishing marker for human myeloid cells and mediates neutrophil adhesion to dendritic cells.
What is CD30 test?
CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree.
What is CD30 a marker for?
CD30 is the characteristic marker of classical Hodgkin lymphoma, anaplastic large-cell lymphoma, and embryonal cell carcinoma, and it is expressed on a subset of aggressive T- and B-cell neoplasms. Its restricted expression on normal cells makes it an attractive candidate for targeted therapy.
What is CD30+ lymphoma?
CD30+ cutaneous T-cell lymphoma, also known as primary cutaneous anaplastic large cell lymphoma, is a cutaneous (skin) condition characterized by solitary or localized skin lesions that have a tendency to ulcerate.
What is PTCL lymphoma?
Peripheral T-cell lymphomas (PTCLs) are uncommon and aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called “T cells” and “natural killer (NK) cells.”
Where is CD30 found?
A protein found on some T cells and B cells (two types of white blood cells). It is a receptor for a protein called tumor necrosis factor, which is involved in cell growth and cell survival. The CD30 protein may be found in higher than normal amounts on some types of cancer cells, including lymphoma cells.
What is the cutoff for CD30 in PTCL?
Studies have used the percentage of positive cells, staining intensity, or both to determine positive cutoff values (≥1%, ≥10%, or 20-25%) ( Table 1 ), but the clinical impact of different criteria is unclear. Figure 1. Representative patterns of CD30 expression in non-ALCL T-cell lymphomas. (A-C) Variable expression patterns of CD30 in PTCL-NOS.
Where does CD30 expression occur in the body?
CD30 is a transmembrane receptor with restricted expression on activated T and B cells in normal lymphoid tissues. 1, 2 In neoplastic conditions, strong CD30 expression is a feature of classical Hodgkin lymphoma and anaplastic large cell lymphomas (ALCL).
Can a peripheral T cell lymphoma coexpress both CD30 and CD15?
Peripheral T-cell lymphomas expressing CD30 and CD15 Coexpression of CD30 and CD15 is typically associated with classic Hodgkin’s lymphoma (HL). Peripheral T-cell lymphomas (PTCLs) can often display histologic features that simulate classic HL. However, reports of PTCLs coexpressing both CD30 and CD15 have been infrequently described.
How is CD30 mRNA and protein expression correlated?
CD30 mRNA and protein expression are highly correlated. The extended use of brentuximab-vedotin was reported for CD30 + nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising efficacy.